Recent News

• 10.01.2025 - C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
• 10.01.2025 - C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
• 09.20.2025 - Phase 1 Trial Data of Cemsidomide in Multiple Myeloma Presented at IMS 2025
• 09.20.2025 - Phase 1 Trial Data of Cemsidomide in Multiple Myeloma Presented at IMS 2025
• 09.20.2025 - C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
• 09.20.2025 - C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
• 09.04.2025 - C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
• 09.04.2025 - C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
• 09.03.2025 - C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting
• 09.03.2025 - C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Recent Filings

• 09.22.2025 - 8-K Current report
• 09.22.2025 - EX-99.1 EX-99.1
• 09.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 07.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors